Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any hypertrophic cardiomyopathy in which the cause of the disease is a mutation in the MYH7 gene.
Features include: Subvalvular aortic stenosis, Asymmetric septal hypertrophy, Congestive heart failure, and Arrhythmia and 1 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Heart and blood vessels | 3 | Subvalvular aortic stenosis, Congestive heart failure, Arrhythmia |
Laing distal myopathy is characterized by muscle weakness and atrophy beginning in the lower legs . Onset is often before age five years. In a few children, onset has been so early as to delay walking. In two families, weakness was not recognized until the teenage years . In one family with 20 affected members, onset of lower-limb weakness occurred between early childhood and the fourth decade . Onset as late as the sixth decade has been described . More than 200 individuals have been identified with a pathogenic variant in MYH7 associated with Laing distal myopathy. The following description of the phenotypic features associated with this condition is based on the reports of , , and . Table 2. Laing Distal Myopathy: Frequency of Select Features
Feature | % of Persons w/Feature | Comment |
|---|---|---|
Lower leg muscle weakness atrophy | 100% | — |
Finger extensor weakness | 100% | Variable time of onset |
Mild facial weakness | 80% | — |
Neck flexor weakness | 100% | — |
Proximal muscle weakness | 100% | — |
Spinal manifestations | ~30% | — |
Cardiac problems | 30% | Lower leg weakness follows a typical sequence: initially dorsiflexion of the ankle and great toe is affected and leads to a high-stepping gait, dropped big toe, and secondary tightening of the Achilles tendon . |
Source: GeneReviews — "Laing Distal Myopathy"
CAV3 encodes caveolin 3 (151 aa). May act as a scaffolding protein within caveolar membranes. Interacts directly with G-protein alpha subunits and can functionally regulate their activity. Highest expression in Muscle Skeletal (46.5 TPM) and Heart Left Ventricle (13.0 TPM).
Hypertrophic cardiomyopathy 1 is associated with mutations in the CAV3 gene on chromosome 3.
The CAV3 protein participates in DYSF, CAV3 and TRIM72 bind, CaV3.2 (CACNA1H:CACNA2D1:CACNB1,2,3:CACNG7) transports calcium from the extracellular region to the cytosol, and CaV3.2:heparan sulfate-HSPG2 pathways.
CAV3 is classified as a druggable target (Cell Surface and Transporter categories) with score 0.0.
MYH7 encodes myosin heavy chain 7 (1,935 aa). Myosins are actin-based motor molecules with ATPase activity essential for muscle contraction. Highest expression in Heart Left Ventricle (4,514 TPM) and Muscle Skeletal (3,693 TPM).
Hypertrophic cardiomyopathy 1 is associated with mutations in the MYH7 gene on chromosome 14.
MYH7 is classified as a druggable target (Druggable Genome category) with score 2.5.
MYLK2 encodes myosin light chain kinase 2 (596 aa). Implicated in the level of global muscle contraction and cardiac function. Phosphorylates a specific serine in the N-terminus of a myosin light chain Highest expression in Muscle Skeletal (252.2 TPM) and Pancreas (3.9 TPM).
Hypertrophic cardiomyopathy 1 is associated with mutations in the MYLK2 gene on chromosome 20.
MYLK2 is classified as a druggable target (Druggable Genome, Enzyme, Kinase, and Serine Threonine Kinase categories) with score 0.0.
Laing distal myopathy may be caused by different types of variants in the distal myosin tail. These include missense changes that insert proline, or cause charge changes or deletion or insertion of amino acids . Charge reversal pathogenic variants in MYH7 including , , and can be associated with a Laing distal myopathy phenotype combined with cardiomyopathy [, , , ]. It has also been shown that missense pathogenic variants to proline and amino acid deletions (, ) or insertions can also be associated with a combined distal myopathy/cardiomyopathy phenotype .
Source: GeneReviews — "Laing Distal Myopathy"
Penetrance appears to be at least 85%. reported a large Spanish family in which the age of onset ranged from birth to the sixth decade; 15% of family members with the pathogenic variant were reported to be asymptomatic. (Note, however, that individual ages at the time of reporting were not clearly stated.) In one apparent instance of a de novo pathogenic variant, the supposedly unaffected father was found to have somatic mosaicism; however, when examined, he did have mild weakness .
Source: GeneReviews — "Laing Distal Myopathy"
No consensus clinical diagnostic criteria for Laing distal myopathy have been published.
Laing distal myopathy should be considered in individuals with the following findings .
Clinical findings
Source: GeneReviews — "Laing Distal Myopathy"
Other disorders to consider in the differential diagnosis of Laing distal myopathy are indicated in this section. Congenital Myopathy The early onset of Laing distal myopathy means that any of the milder congenital myopathies may be a differential diagnosis . Table 4a. Congenital Myopathies of Interest in the Differential Diagnosis of Laing Distal Myopathy
Gene(s) | Disorder | MOI | Comment |
|---|---|---|---|
MTM1 | Centronuclear myopathy (CNM); e.g., CNM1 (OMIM 160150) XL myotubular myopathy | ADXL | Ptosis restriction of eye movements are common. |
NEB | Distal nebulin myopathy 2 (OMIM 256030) | AR | Muscle biopsy shows nemaline bodies. |
RYR1 | Central core disease (OMIM 117000) |
Genetic testing for CAV3, MYH7, MYLK2 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for hypertrophic cardiomyopathy 1 has been reported in the published literature.
No approved treatments are currently available for hypertrophic cardiomyopathy 1. The disease remains an area of unmet medical need.
No clinical practice guidelines for Laing distal myopathy have been published.
To establish the extent of disease and needs in an individual diagnosed with Laing distal myopathy, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Table 5.
Recommended Evaluations Following Initial Diagnosis in Individuals with Laing Distal Myopathy
System/Concern | Evaluation | Comment
| Full neurologic exam review of early gross motor milestones | Exam should specifically look for tightening of Achilles tendon pattern of muscle weakness.
| Baseline eval w/cardiologist incl EKG echocardiogram |
Genetic
counseling | By genetics professionals1 | To inform affected persons their families re nature, MOI, implications of Laing distal myopathy to facilitate medical personal decision making
MOI = mode of inheritance
1. Medical geneticist, certified genetic counselor, or certified advanced genetic nurse
Treatment of Manifestations
Table 6.
Treatment of Manifestations in Individuals with Laing Distal Myopathy
Manifestation/Concern | Treatment | Considerations/Other
| Physiotherapy | To prevent or treat tightening of Achilles tendon
Lightweight splinting of ankle (w/ankle-foot orthosis) | Considered for those w/more advanced disease
| Standard medical treatment under supervision of cardiologist |
| Surgical stabilization of spine | Bracing is ge...
Source: GeneReviews — "Laing Distal Myopathy"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Laing Distal Myopathy"
View trials for hypertrophic cardiomyopathy 1
Table 7. Recommended Surveillance for Individuals with Laing Distal Myopathy
System/Concern | Evaluation | Frequency |
|---|---|---|
Distal myopathy | Neurology eval | Annually |
Cardiomyopathy | Cardiology eval incl EKG echocardiogram | If symptoms of cardiac insufficiency occur |
Scoliosis /or kyphoscolisois | Eval | During years of rapid growth in adolescence |
Sleep-related respiratory insufficiency / Obstructive sleep apnea | Respiratory function assessment | If symptoms suggest sleep apnea / sleep-related respiratory insufficiency |
Source: GeneReviews — "Laing Distal Myopathy"
No clinical trials have been registered for hypertrophic cardiomyopathy 1.
129 publications have been identified in PubMed for hypertrophic cardiomyopathy 1. Research spans Basic Science / Preclinical (36%), Epidemiology / Natural History (22%), and Case Report / Case Series (16%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 47 | 36% |
Disease patterns and progression | 29 | 22% |
Patient case studies | 20 | 16% |
Research summaries | 11 | 9% |
Clinical study results | 11 | 9% |
Testing and diagnosis research | 6 | 5% |
New treatment approaches | 4 | 3% |
Other research | 1 | 1% |
Babur Güler G (2026). [PMID: 41636064](https://pubmed.ncbi.nlm.nih.gov/41636064/). *Anatolian journal of cardiology*. [Epidemiology / Natural History]
Hao L (2026). [PMID: 41695390](https://pubmed.ncbi.nlm.nih.gov/41695390/). *Frontiers in cell and developmental biology*. [Basic Science / Preclinical]
Killian M (2026). [PMID: 41196521](https://pubmed.ncbi.nlm.nih.gov/41196521/). *Irish journal of medical science*. [Epidemiology / Natural History]
Zaoralová M (2026). [PMID: 41757069](https://pubmed.ncbi.nlm.nih.gov/41757069/). *bioRxiv : the preprint server for biology*. [Clinical Trial Publication]
Aranzazu-Ceballos AD (2026). [PMID: 41766641](https://pubmed.ncbi.nlm.nih.gov/41766641/). *Cardiology in the young*. [Case Report / Case Series]
Beuren T (2026). [PMID: 41880433](https://pubmed.ncbi.nlm.nih.gov/41880433/). *Arq Bras Cardiol*. [Epidemiology / Natural History]
Meharwade T (2026). [PMID: 41985226](https://pubmed.ncbi.nlm.nih.gov/41985226/). *Stem Cell Res*. [Basic Science / Preclinical]
Puchnerova V (2026). [PMID: 41759561](https://pubmed.ncbi.nlm.nih.gov/41759561/). *Am J Cardiol*. [Epidemiology / Natural History]
Carella MC (2026). [PMID: 41899251](https://pubmed.ncbi.nlm.nih.gov/41899251/). *J Clin Med*. [Review / Meta-Analysis]
Xu Y (2026). [PMID: 41270882](https://pubmed.ncbi.nlm.nih.gov/41270882/). *Clin Chim Acta*. [Epidemiology / Natural History]
Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 5:58 AM UTC
Online Mendelian Inheritance in Man
Weakness is more proximal than distal, affecting hip girdle in particular; muscle biopsy shows central cores. |
Distal Myopathies of Interest in the Differential Diagnosis of Laing Distal Myopathy Gene | Disorder1 | MOI | Mean Age at Onset |
MYH7 | Laing distal myopathy | AD | 5 yrs |
Udd distal myopathy – tibial muscular dystrophy | AD | 35 yrs | Anterior compartment in legs |
GNE | GNE myopathy (Nonaka distal myopathy) | AR | 20 yrs |
TTN | Myofibrillar myopathies2 (OMIM PS601419) | ADAR | Mostly adulthood, rarely teens |
DYS1 | Miyoshi myopathy (See Dysferlinopathy.) | AR | Late teens, early adulthood |
TIA1 | Welander distal myopathy3 (OMIM 604454) | ADAR | 40 yrs |
ANO5 | Distal anoctaminopathy (See ANO5 Muscle Disease.) | AR | 20 yrs |
Source: GeneReviews — "Laing Distal Myopathy"
AI-curated news mentioning hypertrophic cardiomyopathy 1
Updated Sep 15, 2026
A study identifies natural missplicing events exacerbated by a deep-intronic variant in the MYBPC3 gene as a cause of hypertrophic cardiomyopathy. This discovery enhances understanding of the genetic mechanisms underlying this condition.
A recent study highlights left atrium myocardial remodeling as a prognostic marker in pediatric hypertrophic cardiomyopathy, utilizing CMR feature tracking. This research could enhance monitoring and treatment strategies for affected children.
A new care pathway has been established for diagnosing and managing patients with hypertrophic phenotype in the Marche Region, as reported by the Marche Cardiomyopathies Network. This initiative aims to improve patient outcomes through a structured approach.
Braveheart Bio, Attovia Therapeutics, and Vogenx are preparing for IPOs to enter competitive markets in hypertrophic cardiomyopathy and cardiometabolic diseases. Braveheart aims to rival Bristol Myers Squibb, while Attovia targets Sanofi and Regeneron's Dupixent.
Servier has entered a $2.65 billion deal with Edgewise Therapeutics, allowing Edgewise to pivot towards cardiovascular programs, including EDG-7500 for hypertrophic cardiomyopathy. This non-dilutive capital will enable Edgewise to advance its pipeline significantly.